AbbVie vs Johnson & Johnson ABBV vs JNJ
AbbVie and Johnson & Johnson on one sheet: valuation multiples, growth, margins, debt, dividends and returns, each section labelled with the period it covers, from the companies' filings. Add or remove a stock above the sheet; the link holds the set.
What differs most
- Trailing P/E: AbbVie 80.8×, Johnson & Johnson 40.5×.
- Net margin: Johnson & Johnson 16.2%, AbbVie 9.8%.
- One-year price return: Johnson & Johnson +39.9%, AbbVie +25.8%.
- Operating margin: AbbVie 35.1%, Johnson & Johnson 25.5%.
Price return
2025-10-26 → 2026-10-26
ABBV+25.8%
JNJ+39.9%
Profile
latestSector
Healthcare
Healthcare
Industry
Drug Manufacturers - General
Drug Manufacturers - General
Market value
$506.79B
$641.07B
Enterprise value
$571.04B
$668.81B
Employees
57,000
141,700
Revenue per employee (TTM)
$1.1M
$701K
Our models
nightlythe valuation on each stock's pagePrice vs model
12% overvalued vs model
5% overvalued vs model
Model range
$140–678
$142–546
Models in the headline
1
1
FCF growth priced in, at a 10% return
18.2%
19.3%
Every model, its assumptions and its range: ABBV valuation · JNJ valuation. The growth priced in, at any return: ABBV reverse DCF · JNJ reverse DCF.
Trading
close 2026-10-26Last close
$286.74
$266.30
52-week high
$289.08
$278.43
52-week low
$197.38
$186.00
Price vs 52-week high
−0.8%
−4.4%
Price vs 52-week low
+45.3%
+43.2%
Average daily volume / shares
0.3%
0.3%
Beta
0.28
0.23
Returns
to 2026-10-261 month
+8.5%
−1.8%
3 months
+10.6%
+1.1%
6 months
+44.3%
+17.1%
Year to date
+25.5%
+28.7%
1 year
+25.8%
+39.9%
1 year, dividends added
+28.8%
+42.6%
2 years
+52.6%
+65.5%
Valuation
ABBV price × TTM to Jun 2026 · JNJ price × TTM to Sep 2026P/E (TTM)
80.8×
40.5×
P/E on consensus EPS (next FY)
20.6×
24.0×
Price / sales
7.9×
6.5×
EV / sales
8.9×
6.7×
EV / EBITDA
27.0×
21.5×
Price / book
—
7.9×
Price / free cash flow (FY)
28.4×
32.5×
Free-cash-flow yield (FY)
3.5%
3.1%
Growth
TTM and FY2025Revenue growth (TTM)
—
—
Revenue growth, consensus next FY
+10.6%
+7.5%
Revenue, 3-year CAGR
1.8%
5.6%
Revenue, 5-year CAGR
6.0%
2.7%
EPS growth (TTM)
—
—
EPS growth, consensus next FY
+487.3%
+0.7%
EPS, 3-year CAGR
−29.0%
17.9%
Free cash flow, 3-year CAGR
−9.8%
4.7%
Diluted shares, 3-year change
−0.2%
−8.8%
Profitability
ABBV TTM to Jun 2026 · JNJ TTM to Sep 2026Gross margin (FY)†
70.2%
67.9%
Operating margin
35.1%
25.5%
EBITDA margin
32.9%
31.2%
Net margin
9.8%
16.2%
Free-cash-flow margin (FY)
29.1%
20.9%
Return on equity
—
19.7%
Return on assets
4.7%
8.2%
Asset turnover
0.48
0.50
† Gross margin (FY): As filed. Companies draw the cost-of-revenue line in different places, so gross margins of two companies in one industry can differ for that reason alone; operating margin does not depend on where the line is drawn.
Balance sheet
ABBV MRQ Jun 2026 · JNJ MRQ Sep 2026Cash
$6.57B
$16.91B
Total debt
$70.82B
$44.65B
Net debt
$64.25B
$27.74B
Debt / equity
—
0.5×
Net debt / EBITDA (TTM)
3.0×
0.9×
Interest coverage (FY)
6.9×
26.4×
Current ratio (FY)
0.67
1.03
Dividends
trailing 12 monthsDividend yield
2.4%
2.0%
Dividends per share
$6.92
$5.28
Payout ratio (of TTM EPS)
194.9%
80.3%
Dividend per share, 5-year CAGR
5.9%
5.0%
Frequency
Quarterly
Quarterly
Ownership and activity
last 90 days · latest 13FTracked superinvestors holding (13F)
8
15
Insider open-market buys (Form 4)
$0
$0
Insider sales (Form 4)
$8.2M
$62.0M
Analyst upgrades
2
0
Analyst downgrades
0
0
Statements
ABBV income TTM to Jun 2026 · cash flow FY2025 · JNJ income TTM to Sep 2026 · cash flow FY2025Revenue
$64.39B
$99.33B
EBITDA
$21.18B
$31.04B
Operating income
$22.63B
$25.32B
Net income
$6.31B
$16.09B
EPS (diluted)
$3.55
$6.58
Operating cash flow
$19.03B
$24.53B
Capital expenditure
−$1.21B
−$4.83B
Free cash flow
$17.82B
$19.70B
Dividends paid
$11.66B
$12.38B
Statements, prices, dividends and consensus estimates from Financial Modeling Prep; insider trades from Form 4 and holdings from 13F. Refreshed nightly. A comparison of filed numbers, not a recommendation to buy, sell or hold any security.